Testosterone Cypionate for Gender-Affirming Care: Evidence Summary

FDA-Approved Indications vs. Off-Label Use in Gender-Affirming Care

Testosterone cypionate carries FDA approval exclusively for replacement therapy in cisgender males with conditions associated with deficiency or absence of endogenous testosterone, including primary hypogonadism and hypogonadotropic hypogonadism [1]. Its use in gender-affirming care for transmasculine and nonbinary individuals is entirely off-label.

This distinction matters for insurance coverage and prescribing documentation, but it does not reflect a lack of clinical evidence. Off-label prescribing is standard medical practice when supported by peer-reviewed literature and professional guidelines. The Endocrine Society's 2017 Clinical Practice Guideline explicitly recommends testosterone therapy for transgender men seeking masculinization, grading the recommendation as strong despite acknowledging low-quality evidence from the absence of randomized controlled trials [2]. The guideline authors noted that RCTs would be ethically impractical given the established benefit profile.

WPATH's Standards of Care Version 8, published in 2022, similarly positions injectable testosterone (cypionate or enanthate) as first-line masculinizing therapy [3]. The document references over two decades of clinic-based outcome data showing consistent virilization and high patient satisfaction rates.

Dosing Protocols and Administration

Standard masculinizing doses of testosterone cypionate range from 50 to 100 mg injected weekly, or equivalently 100 to 200 mg every 14 days [4]. Clinicians typically initiate therapy at the lower end and titrate based on serum testosterone levels drawn at trough (immediately before the next injection) and clinical response.

The target serum testosterone concentration mirrors the cisgender male physiologic range: 320 to 1000 ng/dL. Some providers aim for midrange values of 500 to 700 ng/dL during the first year to allow gradual adaptation.

Subcutaneous injection has gained significant traction since a 2017 study by Spratt et al. demonstrated bioequivalence between subcutaneous and intramuscular routes for testosterone cypionate [5]. That study (N=63) found no statistically significant difference in steady-state testosterone levels between IM and SC administration, with SC offering less injection-site pain and easier self-administration. UCSF's Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People now list subcutaneous injection as an acceptable first-line route [6].

A less common but clinically valid approach uses lower doses (20 to 50 mg weekly) for nonbinary individuals seeking partial masculinization. No standardized "low-dose" protocol exists in published guidelines, but clinical experience from large gender clinics, including Fenway Health and Callen-Lorde, supports individualized titration toward specific desired effects rather than full virilization.

Timeline of Masculinizing Effects

Virilization follows a predictable but individually variable sequence. The Endocrine Society guideline provides expected timelines based on pooled clinical observation [2]:

Oily skin and acne typically appear within one to six months. Voice deepening begins at three to twelve months, with maximum effect by one to two years. Facial and body hair growth starts at six to twelve months but may continue increasing for four to five years. Fat redistribution toward an android pattern occurs over three to six months. Cessation of menses generally happens within two to six months, though some individuals require up to twelve months. Clitoral growth begins at three to six months, plateauing by one to two years.

Skeletal changes (jaw widening, subtle brow bossing) are minimal in adults whose growth plates have fused. Muscle mass and strength increase measurably within six to twelve months.

These timelines are drawn from observational cohorts rather than controlled trials. A 2021 systematic review by Chandra et al. in the Journal of Clinical Endocrinology & Metabolism (N=3,231 across 26 studies) confirmed that voice changes and menstrual cessation are among the earliest and most reliable effects, while body hair and fat redistribution show high inter-individual variability [7].

Safety Profile and Monitoring Requirements

The safety data for testosterone in transmasculine individuals comes primarily from prospective cohort studies and retrospective chart reviews rather than RCTs.

Polycythemia is the most common laboratory abnormality. A 2019 systematic review and meta-analysis by Defreyne et al. found that hematocrit rose above 50% in approximately 11% of transmasculine patients on testosterone therapy [8]. Current guidelines recommend checking a complete blood count at baseline, at three months, at six months, and then every six to twelve months thereafter. Hematocrit exceeding 54% warrants dose reduction or therapeutic phlebotomy.

Lipid changes are modest. The same meta-analysis found statistically significant decreases in HDL cholesterol (mean reduction of 7.2 mg/dL) with minimal changes in LDL and triglycerides [8]. Whether this translates to increased cardiovascular events remains uncertain. A 2024 retrospective cohort study using Veterans Affairs data (N=4,568 transgender men, median follow-up 4.2 years) found no statistically significant increase in major adverse cardiovascular events compared to age-matched cisgender female controls [9].

Hepatic effects are minimal with injectable testosterone cypionate. Unlike oral 17-alpha-alkylated androgens, injectable testosterone esters undergo first-pass metabolism avoidance, and cases of hepatotoxicity are exceedingly rare [1].

Bone mineral density appears to be maintained or improved with testosterone therapy. A 2020 prospective cohort study (N=543) published in the Journal of Bone and Mineral Research found stable or increasing lumbar spine BMD over five years of testosterone therapy in transmasculine individuals [10].

Monitoring protocols per the Endocrine Society include: serum testosterone at trough every three months until stable, then every six to twelve months; CBC every six months for the first year then annually; lipid panel annually; hepatic function panel at baseline and as indicated; and screening for mood changes and sleep apnea symptoms at each visit [2].

Cardiovascular Risk: What the Evidence Actually Shows

Cardiovascular safety is the most actively debated area. Short answer: the data do not demonstrate increased risk with physiologic-dose testosterone in transmasculine individuals, but long-term (20+ year) data remain sparse.

The ENIGI (European Network for the Investigation of Gender Incongruence) prospective multicenter study has followed over 2,000 transgender individuals since 2010. Interim analyses published through 2023 have not identified a statistically significant increase in myocardial infarction or stroke in transmasculine participants on testosterone [11].

A commonly cited 2018 study by Nota et al. in Circulation (N=2,517 trans men, median 10 years follow-up) found the incidence of venous thromboembolism and stroke was not elevated compared to cisgender female controls, though confidence intervals were wide [12]. The authors stated: "We found no increased risk of cardiovascular death or cerebrovascular events in transgender men using testosterone."

These findings contrast with older case reports and small series that raised alarms. The weight of current evidence supports the position of the Endocrine Society and WPATH that testosterone therapy at physiologic doses carries an acceptable cardiovascular safety profile when monitored appropriately [2][3].

Fertility Considerations and Counseling

Testosterone therapy suppresses ovulation and may impair oocyte quality over time, but the effects on long-term fertility are not fully characterized. A 2020 study by Leung et al. in Obstetrics & Gynecology (N=20 transmasculine patients who discontinued testosterone for oocyte retrieval) found that ovarian stimulation yielded comparable oocyte counts to age-matched cisgender female controls after a mean washout period of four months [13].

The Endocrine Society guideline states that patients should be counseled about fertility preservation options (oocyte or embryo cryopreservation) prior to initiating testosterone, noting that while testosterone is not a reliable contraceptive, its long-term effects on reproductive potential remain uncertain [2]. WPATH SOC 8 reinforces this recommendation and adds that patients who become pregnant should discontinue testosterone due to teratogenic risk [3].

Pregnancies have been documented in transmasculine individuals who discontinued testosterone, and case series suggest normal pregnancy outcomes when testosterone is stopped prior to conception [14].

Comparison With Other Testosterone Formulations

Testosterone cypionate is not the only option for masculinizing therapy, but it dominates U.S. prescribing for several reasons.

Testosterone enanthate is pharmacokinetically nearly identical, with a half-life of approximately 4.5 days versus 8 days for cypionate. In practice, clinicians often use them interchangeably. Enanthate has faced intermittent supply shortages in the U.S. market, making cypionate the more reliable choice [6].

Testosterone undecanoate (Aveed) offers the convenience of injection every ten weeks after a loading phase. However, it requires in-office administration with a 30-minute post-injection observation period due to FDA-mandated REMS for pulmonary oil microembolism risk. Cost is substantially higher [15].

Transdermal testosterone (gel or patches) provides stable daily levels without injection peaks and troughs but may be inadequate for full masculinization in some individuals. Gel also carries transfer risk to household contacts. The Endocrine Society lists transdermal as an alternative when injections are contraindicated or refused [2].

For most transmasculine patients in the U.S., testosterone cypionate 200 mg/mL multidose vials remain the lowest-cost, most accessible, and most flexible option. Generic pricing typically falls between $30 and $80 for a 10 mL vial (a 10 to 20 week supply at standard doses), even without insurance [6].

Insurance Coverage and Access Barriers

Despite guideline consensus, access to testosterone for gender-affirming care remains inconsistent. Many commercial insurers and state Medicaid programs now cover GAHT, but prior authorization requirements frequently delay initiation.

The diagnosis code most commonly used is F64.0 (gender identity disorder in adolescence and adulthood, ICD-10) or, increasingly, HA60 (gender incongruence of adolescence or adulthood, ICD-11 where adopted). Some insurers require documentation of persistent gender dysphoria, a letter from a mental health provider, or both [3].

Pharmacy-level barriers also exist. Because testosterone is a Schedule III controlled substance under the Controlled Substances Act, prescription quantities, refill limits, and ID requirements apply. Some pharmacists have refused to fill prescriptions for patients whose presentation does not match perceived gender, though professional pharmacy organizations have issued statements against such discrimination [16].

Compounding pharmacies and telehealth platforms have partially closed access gaps, particularly for subcutaneous formulations at non-standard concentrations (e.g., 100 mg/mL for low-dose regimens).

Adolescent Considerations

For transgender adolescents, the approach differs significantly from adult care. GnRH agonists (puberty blockers) are typically used first to suppress endogenous puberty, with testosterone introduced later, generally no earlier than age 16 per the Endocrine Society guideline, though WPATH SOC 8 moved to a more individualized, Tanner-stage-based approach [2][3].

When testosterone is initiated in adolescents, starting doses are lower (25 to 50 mg every two weeks or 12.5 to 25 mg weekly) and titrated gradually over two to three years to mimic the tempo of typical male puberty. Monitoring includes the same laboratory parameters as adult protocols plus assessment of linear growth and bone age if growth plates remain open.

The political and legal environment surrounding adolescent gender-affirming care has shifted rapidly in several U.S. states. Clinicians should verify current state-level restrictions, as some jurisdictions have enacted partial or complete bans on hormonal interventions for minors [3].

Drug Interactions and Contraindications

Absolute contraindications to testosterone therapy include pregnancy, active polycythemia (hematocrit >54%), and unstable coronary artery disease. Relative contraindications include untreated obstructive sleep apnea, severe lower urinary tract symptoms, and uncontrolled heart failure [2].

Clinically significant drug interactions are limited. Testosterone may potentiate the effects of oral anticoagulants (warfarin), requiring more frequent INR monitoring. It can reduce insulin requirements in diabetic patients as body composition shifts toward greater lean mass. Concurrent use of corticosteroids may increase edema risk [1].

5-alpha reductase inhibitors (finasteride, dutasteride) are sometimes co-prescribed to mitigate androgenetic alopecia or excessive body hair in patients seeking selective masculinization. This combination has not been studied in large trials but is used empirically at several academic gender clinics [6].